IMNN

+ Watchlist + Portfolio

Imunon, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.57
52-Week Range: $1.47 – $6.96
Market Cap: $8.87M
P/E (TTM): —
EPS (TTM): -2.92
Dividend Yield: —

Advanced Metrics

Price/Book: 3.81
PEG Ratio: 5.03
Return on Equity: -429.72%
Return on Assets: -77.99%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.82
Debt/Equity: 1.87
Total Debt: $7.85M
Free Cash Flow: $-9.53M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $12.04M

IMNN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$500.00K	$0.00	$0.00	$0.00
Research & Development	$11.73M	$11.29M	$11.64M	$7.78M
Selling, General & Admin	$13.69M	$9.74M	$7.49M	$6.87M
Operating Expenses	$25.42M	$21.03M	$19.13M	$14.65M
Operating Income	-$24.92M	-$21.03M	-$19.13M	-$14.65M
EBITDA	-$31.71M	-$19.88M	-$18.41M	-$13.95M
Pretax Income	-$37.47M	-$20.80M	-$18.62M	-$14.50M
Income Tax	-$1.57M	-$1.28M	$0.00	—
Net Income	-$35.90M	-$19.51M	-$18.62M	-$14.50M
Diluted EPS	-65.61	-28.17	-21.13	-6.83
Diluted Shares	547630	693474	882280	2.12M

IMNN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.49M	$5.84M	$5.87M	$8.78M
Receivables	$128.93K	$0.00	—	—
Current Assets	$36.78M	$18.24M	$8.01M	$10.72M
Total Assets	$43.98M	$21.92M	$9.72M	$12.29M
Current Liabilities	$10.04M	$7.39M	$4.79M	$4.62M
Long-Term Debt	$4.61M	—	—	—
Total Debt	$6.27M	$1.62M	$1.14M	$1.01M
Total Liabilities	$14.65M	$8.53M	$5.47M	$5.23M
Retained Earnings	-$368.67M	-$388.18M	-$406.80M	-$421.30M
Shareholders' Equity	$29.33M	$13.39M	$4.24M	$7.06M
Working Capital	$26.74M	$10.85M	$3.22M	$6.10M

IMNN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.10M	-$19.02M	-$18.85M	-$13.90M
Capital Expenditure	-$267.80K	-$451.76K	-$29.54K	-$280.57K
Free Cash Flow	-$23.36M	-$19.47M	-$18.88M	-$14.18M
Depreciation & Amortisation	$731.63K	$720.00K	$718.12K	$698.90K
Stock-Based Compensation	$2.67M	$759.01K	$477.26K	$127.37K
Investing Cash Flow	$8.28M	$11.01M	$9.83M	-$280.57K
Financing Cash Flow	$6.72M	-$3.64M	$9.06M	$17.09M
Dividends Paid	—	—	$0.00	-$10.28K
Share Repurchases	-$28.50M	$0.00	—	—
Net Change in Cash	-$8.09M	-$11.65M	$34.20K	$2.91M

IMNN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.17M	$1.23M	$1.90M	$2.49M	$2.34M
Selling, General & Admin	$1.98M	$1.54M	$1.58M	$1.77M	$1.97M
Operating Expenses	$4.15M	$2.77M	$3.48M	$4.26M	$4.31M
Operating Income	-$4.15M	-$2.77M	-$3.48M	-$4.26M	-$4.31M
EBITDA	-$3.95M	-$2.60M	-$3.31M	-$4.09M	-$4.14M
Pretax Income	-$4.10M	-$2.74M	-$3.43M	-$4.22M	-$4.25M
Net Income	-$4.10M	-$2.74M	-$3.43M	-$4.22M	-$4.25M
Diluted EPS	-3.15	-1.87	-1.16	—	-0.84
Diluted Shares	1.30M	1.47M	2.94M	—	5.03M

IMNN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$2.87M	$4.73M	$5.25M	$8.78M	$4.79M
Current Assets	$5.09M	$6.89M	$7.26M	$10.72M	$6.62M
Total Assets	$6.86M	$8.79M	$8.99M	$12.29M	$8.02M
Current Liabilities	$5.80M	$5.32M	$4.20M	$4.62M	$4.17M
Total Debt	$1.01M	$1.19M	$1.10M	$1.01M	$911.75K
Total Liabilities	$6.41M	$6.13M	$4.91M	$5.23M	$4.66M
Retained Earnings	-$410.91M	-$413.65M	-$417.08M	-$421.30M	-$425.55M
Shareholders' Equity	$452.03K	$2.66M	$4.08M	$7.06M	$3.36M
Working Capital	-$704.93K	$1.57M	$3.06M	$6.10M	$2.45M

IMNN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.85M	-$2.95M	-$4.44M	-$3.66M	-$3.99M
Capital Expenditure	-$259.65K	-$17.33K	—	-$3.59K	—
Free Cash Flow	-$3.11M	-$2.97M	-$4.44M	-$3.66M	-$3.99M
Depreciation & Amortisation	$197.93K	$164.67K	$167.03K	$169.26K	$166.54K
Stock-Based Compensation	$204.53K	$122.64K	-$211.28K	$11.48K	$548.59K
Investing Cash Flow	-$259.65K	-$17.33K	$0.00	-$3.59K	$0.00
Financing Cash Flow	$105.69K	$4.83M	$4.96M	$7.19M	-$1.81K
Dividends Paid	—	—	—	$0.00	—
Net Change in Cash	-$3.00M	$1.86M	$522.15K	$3.53M	-$3.99M

Market Snapshot

About

Imunon, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment. The company's pipeline includes targeted therapies designed to activate the immune system against tumor cells. Imunon utilizes multiple technology platforms including nucleic acid-based approaches and cell-based therapies. The company is advancing candidates through clinical trials for various cancer indications. Imunon aims to develop treatments that offer improved efficacy and safety profiles compared to existing standards of care.